Company

TheraCryf

Biotechnology Research Congleton Road, United Kingdom 8 employees

Employees: 8
Contacts: 2
Emails: 2

evgen.com LinkedIn

TheraCryf Overview

Headquarters: Congleton Road, United Kingdom
Website: evgen.com
Industry: Biotechnology Research
Employees: 8
Founded: 2007
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Pharmaceuticals Cancer and neurological conditions Core technology Sulforadex® Commercialising sulforaphane-based pharmaceuticals

About TheraCryf

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

TheraCryf Contact Details

People in AeroLeads: 3
With contact data: 2
Email contacts: 2; 66.7% coverage

TheraCryf Org Chart

Sample employees and titles

Name	Title	Location	Contact
Glen Clack	Honorary Professor of Translational Medicine at University of Sheffield	Macclesfield, England, United Kingdom	Email
Helen Kuhlman	Cbo - Ned - Investment	United Kingdom	Email
Jan Kenworthy	Clinical Trial Project Manager	United Kingdom	View